A pt (b)(6) was enrolled in the (b)(4) study for stress urinary incontinence.On (b)(6) 2012, the pt was injected with 1.0 ml coaptite, lot 1027423; and on (b)(6) 2012, the pt was injected with 1.0 ml coaptite, lot 1028864.Additionally, on (b)(6) 2014, the pt was injected with 2.0 ml coaptite, lot 1031016.On (b)(6) 2012, the pt developed urinary retention diagnosed by a bladder ultrasound.The pt was treated with foley catheterization and recovered by (b)(6) 2012.Per physician, the event was of mild severity and definitely related to coaptite.On (b)(6) 2012, the pt developed urge incontinence as reported by pt.The pt was treated on (b)(6) 2012 with vesicare x 2 weeks and gelnique topical x 2 weeks and recovered by (b)(6) 2012.Per physician, the event was of mild severity and definitely not related to coaptite.
|
Add'l lot injected on 04/12/2012; 1028864.(expiration date 10/2014, manufactured 10/2011).Add'l lot injected on 05/16/2012: 1031016.(expiration date 02/2015, manufactured 02/2012).The device history records for the three reported lots were reviewed, all required testing specs were met prior to release, there were no abnormalities noted.
|